FINWIRES · TerminalLIVE
FINWIRES

Home First Q4 Profit Soars to INR 1.5 Billion, Beats Estimates

By

-- Home First Finance Company India's (NSE:HOMEFIRST, BOM:543259) profit after tax rose to 1.49 billion Indian rupees in the fiscal fourth quarter ended March 31, from 1.05 billion rupees a year ago.

Earnings per share came in at 14.22 rupees from 11.45 rupees a year ago, the financial services provider said in a filing to the Indian stock exchanges on Wednesday. The EPS was higher than the 14.08 rupees estimated by the analysts polled by Visible Alpha.

Total revenue from operations also increased to 5.01 billion rupees from 2.15 billion rupees a year ago.

The company's board recommended a dividend of 5.20 rupees per share of a face value of 2 rupees each for the financial year ended March 31.

The company's shares were down 2% in recent trade.

Related Articles

International

Business Optimism in Saudi Arabia Improves in April

Saudi Arabia's business confidence index stood at 54.5 points in April, up from 52.1 points in March, data from the General Authority for Statistics showed Thursday.The monthly change in confidence was 4.6% higher, compared with a 14.2% decrease earlier.The statistics agency noted that the reading reflected sustained optimism in the business sector, underpinned by expectations of continued growth in various segments and confidence in the stability of economic activity.

$^TASI
International

German Monthly Factory Orders Rise 5% in March

Germany's monthly factory orders gained 5% in March, following a revised 1.4% increase in February, according to preliminary data from the country's Federal Statistical Office published Thursday.Analysts expected a 1% rise for the month.On a yearly basis, new orders in manufacturing were up 6.3%, against the 3.5% jump earlier.

$^SXXP
Asia

Jointown Pharmaceutical Unit Passes Shandong GMP Inspection

Jointown Pharmaceutical (SHA:600998) unit Beijing Jingfeng Pharmaceutical Shandong passed a good manufacturing practices (GMP) compliance inspection by the Shandong Medical Products Administration for its tablet production lines.The inspection covered Workshop 801, which produces metformin hydrochloride enteric-coated tablets for type 2 diabetes and isosorbide dinitrate tablets for coronary heart disease and angina, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.

$SHA:600998